Barclays lowered the firm’s price target on CVS Health to $100 from $110 and keeps an Overweight rating on the shares. The analyst updated the model following the close of the Signify acquisition, taking a more conservative stance on buybacks overall given the company’s other large pending acquisitions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CVS: